Personalizing dermatology: The future of genomic expression profiling to individualize dermatologic therapy

Journal of Dermatological Treatment

Volumn 23, Issue 3, 2012, Pages 161-167

  Rizzo, Amilcar Ezequiel ^a   Maibach, Howard I ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti aging; Microarray; Pharmacogenomics; Skin care

Indexed keywords

ATOMOXETINE; AZATHIOPRINE; BRCA1 PROTEIN; BRCA2 PROTEIN; CELECOXIB; CETUXIMAB; CLOPIDOGREL; CODEINE SULFATE; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLUOXETINE; GLUCURONOSYLTRANSFERASE 1A1; IMATINIB; IRINOTECAN; K RAS PROTEIN; MERCAPTOPURINE; PANITUMUMAB; THIOPURINE METHYLTRANSFERASE; TRASTUZUMAB; VITAMIN K GROUP; WARFARIN;

ATOPIC DERMATITIS; CATALYST; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL RESEARCH; CUTANEOUS PARAMETERS; DERMATOLOGY; DNA METHYLATION; DNA SEQUENCE; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION AND TRANSLATION; GENETIC VARIABILITY; HUMAN; IN VITRO STUDY; MEDICINE; MICROARRAY ANALYSIS; NONHUMAN; ONCOGENE C KIT; PATIENT COMPLIANCE; PHARMACOGENOMICS; PHARMACOKINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; REVIEW; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; STRATUM CORNEUM; TRANSLATIONAL RESEARCH; WOUND HEALING;

DERMATOLOGY; GENE EXPRESSION PROFILING; GENOME, HUMAN; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; SIGNAL TRANSDUCTION; SKIN; SKIN AGING; SKIN CARE; SKIN DISEASES;

EID: 84861041361     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2010.535806     Document Type: Review

References (38)

1. Jarrold BB, Mullins LA, Reichling TD, Tiesmann JP, Juhlin KD, Binder RL, et al. Genomics analysis of expression of stratum corneum lipid metabolism pathways associated with aging and responses to cosmetic ingredients. Exp Dermatol. 2010; 19 (2): 222.
2. Bauer JW, Laimer M. Gene therapy of epidermolysis bullosa. Expert Opin Biol Ther. 2004; 4 (9): 1435-1443. (Pubitemid 39222976)
3. Liu Y, Krueger JG, Bowcock AM. Psoriasis: Genetic associations and immune system changes. Genes Immun. 2007; 8 (1): 1-12. (Pubitemid 46158098)
4. Courtesy: National Human Genome Research Institute (NHGRI). Funding History, genome.gov. November 12, 2009 [last updated February 4, 2008]. Available from: http://www.genome.gov/Pages/About/Budget/Funding History90-09.pdf.
5. Guttmacher AE, Collins FS. Genomic medicine-a primer. NEngl J Med. 2002; 347 (19): 1512-1520.
6. Lee C, Morton CC. Structural genomic variation and personalized medicine. N Engl J Med. 2008; 358 (7): 740-741. (Pubitemid 351240757)
7. Stein LD. Human genome: End of the beginning. Nature. 2004; 431 (7011): 915-916.
8. Romero PR, Zaidi S, Fang YY, Uversky VN, Radivojac P, Oldfield CJ, et al. Alternative splicing in concert with protein intrinsic disorder enables increased functional diversity in multicellular organisms. Proc Natl Acad Sci U S A. 2006; 103 (22): 8390-8395. (Pubitemid 43838465)
9. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001; 409 (6822): 928-933. (Pubitemid 32165347)
10. Courtesy: National Library of Medicine (NCBI). Single Nucleotide Polymorphism, ncbi.nlm.nih.gov. November 10, 2009 [last updated December 30, 2008]. URL: http://www. ncbi.nlm.nih.gov/SNP.
11. Courtesy: National Human Genome Research Institute (NHGRI). International HapMap Project, genome.gov. November 07, 2009 [last updated September 10, 2009]. URL: http://www.genome.gov/Pages/Research/HapMap.
12. Couzin J. Human genome. HapMap launched with pledges of $100 million. Science. 2002; 298 (5595): 941-942. (Pubitemid 35247269)
13. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995; 270 (5235): 467-470.
14. Duyk GM. Sharper tools and simpler methods. Nat Genet. 2002; 32 (suppl): 465-468. (Pubitemid 35435147)
15. Holloway AJ, van Laar RK, Tothill RW, Bowtell DD. Options available-from start to finish-for obtaining data from DNA microarrays II. Nat Genet. 2002; 32 (suppl): 481-489. (Pubitemid 35435150)
16. Petricoin EF 3rd, Hackett JL, Lesko LJ, Puri RK, Gutman SI, Chumakov K, et al. Medical applications of microarray technologies: A regulatory science perspective. Nat Genet. 2002; 32 (suppl): 474-479. (Pubitemid 35435149)
17. Quackenbush J. Microarray data normalization and transformation. Nat Genet. 2002; 32 (suppl): 496-501. (Pubitemid 35435152)
18. Trent JM, Baxevanis AD. Chipping away at genomic medicine. Nat Genet. 2002; 32: 462. (Pubitemid 35435145)
19. Perkel JM. Molecular diagnostics: Personalizing personalized medicine. Science. 2009; 324 (5928): 815-817.
20. Courtesy: U.S. Food and Drug Administration. Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels, fda.gov. November 5, 2009 [last updated August 18, 2008]. URL: http://www.fda.gov/Drugs/ScienceResearch/ ResearchAreas/Pharmacogenetics/ucm083378.htm.
21. Wang L, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: Insights, challenges and future directions. Oncogene. 2006; 25: 1629-1638.
22. Salavaggione O E, Wang L, Wiepert M, Yee VC, Weinshilboum RM. Thiopurine S-methyltransferase pharmacogenetics: Variant allele functional and comparative genomics. Pharmacogenet Genomics. 2005; 15: 801-815. (Pubitemid 41531729)
23. U.S. Department of Health and Human Services Food and Drug Administration. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research & Center for Devices and Radiological Health. November 2003. Available at: http://www.FDA.gov.
24. Katsanis SH, Javitt G, Hudson K. Public health. A case study of personalized medicine. Science. 2008; 320: 53-54. Erratum in Science. 2008; 320 (5874): 316. (Pubitemid 351492504)
25. Gonzalez FJ. The molecular biology of cytochrome P450s. Pharmacol Rev. 1988; 40: 243-288. (Pubitemid 19086991)
26. Bird A. Perceptions of epigenetics. Nature. 2007; 447 (7143): 396-398. (Pubitemid 46816744)
27. Feldman SR, Horn EJ, Balkrishnan R, Basra MK, Finlay AY, McCoy D, et al. Psoriasis: Improving adherence to topical therapy. J Am Acad Dermatol. 2008; 59 (6): 1009-1016.
28. Carroll CL, Feldman SR, Camacho FT, Balkrishnan R. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol. 2004; 151 (4): 895-897. (Pubitemid 39482127)
29. Lott R, Taylor SL, O'Neill JL, Krowchuk DP, Feldman SR. Medication adherence among acne patients: A review. Br JDermatol. 2004; 151 (4): 895-897.
30. Conde JF, Kaur M, Fleischer AB Jr, Tusa MG, Camacho F, Feldman SR. Adherence to clocortolone pivalate cream 0.1% in a pediatric population with atopic dermatitis. Cutis. 2008; 81 (5): 435-441.
31. Krejci-Manwaring J, Tusa MG, Carroll C, Camacho F, Kaur M, Carr D, et al. Stealth monitoring of adherence to topical medication: Adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol. 2007; 56 (2): 211-216. (Pubitemid 46074250)
32. Jarrold B, Mullins L, Reichling T, Osborne R. Expression of stratum corneum lipid pathways in human skin equivalent cultures. J Am Acad Dermatol. 2008; 58 (2): AB30.
33. Saaf AM, Tengvall-Linder M, Chang HY, Adler AS, Wahlgren CF, et al. Global expression profiling in atopic eczema reveals reciprocal expression of inflammatory and lipid genes. PLoS One. 2008; 3 (12): e4017.
34. Osborne R, Mullins LA, Jarrold BB. Understanding metabolic pathways for skin anti-aging. J Drugs Dermatol. 2009; 8 (7 suppl): s4-7.
35. Khavari PA. Modeling cancer in human skin tissue. Nat Rev Cancer. 2006; 4 (6): 270-280.
36. Robinson MK, Binder RL, Griffiths CE. Genomic-driven insights into changes in aging skin. J Drugs Dermatol. 2009; 8 (7 suppl): s8-11.
37. Bissett DL, Farmer T, McPhail S, Reichling T, Tiesman JP, Juhlin KD, et al. Genomic expression changes induced by topical N-acetylglucosaminein skin equivalent cultures in vitro. J Cosmet Dermatol. 2007; 6 (4): 232-238. (Pubitemid 350214880)
38. Mullins L, Jarrold B, Linter K, Osborne R. In vitro skin biomarker responses to a new anti-aging peptide, Pal-KT. J Am Acad Dermatol. 2009; 60 (suppl): AB82.